Table 3.
Treatment outcomes (adjusteda mean changes from baseline in rescue medication use and the percentage of awakening-free nights) by FAO category (LLN definition).
| Study I (mild to moderate) |
Study II (moderate to severe) |
|||
|---|---|---|---|---|
| FAO+ (n =116) | FAO− (n =371) | FAO+ (n =226) | FAO− (n =333) | |
| Rescue medication use, inh/d | ||||
| BUD/FM | −2.26 (0.40) | −1.65 (0.16) | −1.11 (0.26) | −1.14 (0.18) |
| BUD | −1.52 (0.38) | −1.34 (0.17) | −0.10 (0.30) | −0.62 (0.18) |
| FM | −1.55 (0.39) | −1.29 (0.17) | −0.65 (0.27) | −0.69 (0.18) |
| Placebo | 0.45 (0.34) | –0.38 (0.17) | 0.57 (0.26) | 0.77 (0.17) |
| Awakening-free nights, % | ||||
| BUD/FM | 20.2 (3.4) | 21.7 (1.3) | 13.6 (2.3) | 12.4 (1.8) |
| BUD | 19.7 (3.2) | 20.9 (1.3) | 16.1 (2.7) | 14.8 (1.8) |
| FM | 14.6 (3.3) | 19.8 (1.4) | 14.6 (2.4) | 9.5 (1.8) |
| Placebo | 12.4 (2.9) | 13.4 (1.3) | 9.8 (2.4) | 5.0 (1.7) |
a
Data presented as least-squares mean (SD) unless otherwise noted.
BUD/FM, budesonide/formoterol; FAO, fixed airflow obstruction; inh/d, inhalations per day; LLN, lower limit of normal.